Prophylactic Indomethacin in Infants Born Extremely Preterm: Risks and Benefits Revisited.

J Pediatr

Department of Pediatrics and Cardiovascular Research Institute, University of California San Francisco, San Francisco, California.

Published: September 2023

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpeds.2023.113568DOI Listing

Publication Analysis

Top Keywords

prophylactic indomethacin
4
indomethacin infants
4
infants born
4
born extremely
4
extremely preterm
4
preterm risks
4
risks benefits
4
benefits revisited
4
prophylactic
1
infants
1

Similar Publications

Background: Link Samahan® (LS), a product of Link Natural Products (Pvt) Limited, Sri Lanka contains extracts of 14 medicinal plants. It is used as a prophylactic against cold and cold related symptoms. It has immunomodulatory activity, specifically enhancing the humoral immune response.

View Article and Find Full Text PDF

Purpose: To assess the rate of heterotopic ossification (HO) following acetabular surgery with a standardized protocol via the Kocher-Langenbeck. Secondarily, to evaluate patient characteristics, injury variables, and perioperative data among patients with HO and no HO.

Methods: This was a retrospective case series from an academic Level I trauma center.

View Article and Find Full Text PDF

Background: Acquired spontaneous intestinal perforation or SIP occurs most commonly in the extremely premature infant population. As the incidence is rising, understanding modifiable factors such as common medication exposures becomes important for individualizing care.

Methods: The primary outcome was SIP in premature infants with exposure to indomethacin, ibuprofen, or acetaminophen.

View Article and Find Full Text PDF
Article Synopsis
  • * Research shows that this treatment can lower mortality rates, improve chances of survival without BPD, and support heart function and urine output, but there are concerns about risks like intestinal perforation and late-onset infections, especially in very premature infants.
  • * While long-term developmental outcomes appear unaffected, ongoing discussions focus on the ideal patient population, timing, duration of treatment, and obstacles to applying this treatment as guidelines evolve.
View Article and Find Full Text PDF

Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication of ERCP, with limited studies comparing combined prophylactic measures and their efficacy relative to individual patient risk profiles. This study aims to perform an individual patient data meta-analysis (IPDMA) to evaluate the contribution of patient and ERCP-related risk factors to PEP development and to identify the best prophylaxis strategies according to the patient's risk profile.

Methods: We systematically searched MEDLINE, Embase, and Cochrane databases until November 2022 for randomized controlled PEP prophylaxis trials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!